AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15037334 — intervention group
Group type: EXPERIMENTAL
Intervention: haloperidol
Number of subjects: 307
Study 15037334 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 307
Study 15037334 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 307
Study 11232870 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% PVP-I
Number of subjects: 5
Study 11232870 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% ethyl alcohol
Number of subjects: 5
Study 11232870 — intervention group
Group type: COMPARATOR
Intervention: Plain liquid soap
Number of subjects: 5
Study 11232870 — intervention group
Group type: COMPARATOR
Intervention: 4% chlorhexidine
Number of subjects: 5
Study 9429043 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg.kg‐1 rocuronium, 3 min before 2 mg.kg‐1 succinylcholine (ROC‐3 min)
Number of subjects: 60
Study 9429043 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg.kg‐1 rocuronium, 1.5 min before 2 mg.kg‐1 succinylcholine (ROC‐1.5 min)
Number of subjects: 60
Study 9429043 — intervention group
Group type: COMPARATOR
Intervention: No rocuronium before 2 mg.kg‐1 succinylcholine (NO ROC)
Number of subjects: 60
Study 8504594 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Hardinge approach
Number of subjects: 100
Study 8504594 — intervention group
Group type: COMPARATOR
Intervention: Transtrochanteric lateral approach
Number of subjects: 100
Study 3622595 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 122
Study 3622595 — intervention group
Group type: COMPARATOR
Intervention: Bromoergocriptine
Number of subjects: 122
Study 3622595 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromoergocriptine plus Domperidone
Number of subjects: 122
Study 3622595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 29935641 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% O2 from D3 to D5
Number of subjects: 203
Study 29935641 — intervention group
Group type: COMPARATOR
Intervention: 5% O2 from D1 to D5
Number of subjects: 203
Study 27035853 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine 266 mg
Number of subjects: 116
Study 27035853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 27035853 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine
Number of subjects: 116
Study 24355800 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric cardiovascular magnetic resonance (CMR) assessment
Number of subjects: 48
Study 24355800 — intervention group
Group type: COMPARATOR
Intervention: Coronary angiography
Number of subjects: 48
Study 24033812 — intervention group
Group type: EXPERIMENTAL
Intervention: Apically positioned flap (APF)
Number of subjects: 30
Study 24033812 — intervention group
Group type: COMPARATOR
Intervention: Modified Widman flap (MWF)
Number of subjects: 30
Study 20116964 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient feedback performance improvement intervention (12 weeks)
Number of subjects: 118
Study 20116964 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group, 12 weeks)
Number of subjects: 118
Study 17712347 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg/day for 10 days
Number of subjects: 29
Study 17712347 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone 80 mg/day for 10 days
Number of subjects: 29
Study 16357337 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamic deep brain stimulation (DBS)
Number of subjects: 0
Study 16357337 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral thalamotomy in the cerebellar thalamus
Number of subjects: 0
Study 15022145 — intervention group
Group type: EXPERIMENTAL
Intervention: No planned interventions (naturalistic observation)
Number of subjects: 271
Study 11738299 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) users
Number of subjects: 293
Study 11738299 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) nonusers
Number of subjects: 293
Study 11738299 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol treatment with ASA
Number of subjects: 293
Study 11738299 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol treatment without ASA
Number of subjects: 293
Study 11738299 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with ASA
Number of subjects: 293
Study 11738299 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment without ASA
Number of subjects: 293
Study 9033324 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin loading dose of 300 U/kg followed by 1 U/mL of heparin in the prime (low-dose group)
Number of subjects: 48
Study 9033324 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin loading dose of 300 U/kg followed by 3 U/mL of heparin in the prime (high-dose group)
Number of subjects: 48
Study 8285609 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufloxacin 400 mg on day 1 and 200 mg daily for 9 days (n = 64)
Number of subjects: 192
Study 8285609 — intervention group
Group type: EXPERIMENTAL
Intervention: Rufloxacin 300 mg on day 1 and 150 mg daily for 9 days (n = 63)
Number of subjects: 192
Study 8285609 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 500 mg three times a day for 10 days (n = 65)
Number of subjects: 192
Study 3300566 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis with relaxation therapy
Number of subjects: 15
Study 3300566 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 15
Study 3300566 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up examination
Number of subjects: 15
Study 30365341 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 176
Study 30365341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 27580889 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tumor volume (≥15cc)
Number of subjects: 497
Study 27580889 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline tumor volume (<15cc)
Number of subjects: 497
Study 27580889 — intervention group
Group type: EXPERIMENTAL
Intervention: Large tumors (≥15cc)
Number of subjects: 497
Study 27580889 — intervention group
Group type: COMPARATOR
Intervention: Cabozantinib
Number of subjects: 497
Study 25565416 — intervention group
Group type: EXPERIMENTAL
Intervention: FitBack intervention
Number of subjects: 597
Study 25565416 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 597
Study 25565416 — intervention group
Group type: COMPARATOR
Intervention: Alternative care group
Number of subjects: 597
Study 23891062 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered 50% nitrous oxide
Number of subjects: 100
Study 23891062 — intervention group
Group type: COMPARATOR
Intervention: Conventional infiltrative anaesthesia with 1% prilocaine hydrochloride
Number of subjects: 100
Study 21087856 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon α2b (IFN)
Number of subjects: 211
Study 21087856 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 211
Study 21087856 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial determination of S100B
Number of subjects: 211
Study 19247544 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness centre-based exercise programme (supervised by a personal trainer, 3 times per week for 12 weeks)
Number of subjects: 62
Study 19247544 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise programme (unsupervised at home, similar exercise programme)
Number of subjects: 62
Study 19247544 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness centre-based exercise programme
Number of subjects: 62
Study 19247544 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise programme
Number of subjects: 62
Study 17254453 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 1 g/kg
Number of subjects: 242
Study 17254453 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG 2 g/kg
Number of subjects: 242
Study 15968598 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CAD
Number of subjects: 69
Study 15968598 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CAD with decreased LVEF (dEF)
Number of subjects: 69
Study 15968598 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CAD with normal LVEF (nEF) and an average filling rate (AFR) <= 1.04 EDV/s
Number of subjects: 69
Study 15968598 — intervention group
Group type: EXPERIMENTAL
Intervention: Total CAD group
Number of subjects: 69
Study 15968598 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CAD with normal LVEF (nEF)
Number of subjects: 69
Study 11824887 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (DTIC)
Number of subjects: 61
Study 11824887 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (DTIC) + Interferon-alpha (IFN-alpha)
Number of subjects: 61
Study 9625835 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum p53 antibodies positive patients (33 out of 57)
Number of subjects: 57
Study 9625835 — intervention group
Group type: COMPARATOR
Intervention: Tumor markers (CEA, SCC-Ag, CYFRA21-1)
Number of subjects: 57
Study 8003109 — intervention group
Group type: COMPARATOR
Intervention: Glucose only (2 mg/kg BW/min)
Number of subjects: 23
Study 8003109 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose and xylitol mixture (1:1; 2 mg/kg BW/min)
Number of subjects: 23
Study 8003109 — intervention group
Group type: COMPARATOR
Intervention: Glucose-containing electrolyte solution (0.8 mg/kg BW/min)
Number of subjects: 23
Study 8003109 — intervention group
Group type: COMPARATOR
Intervention: Glucose (4 mg/kg BW/min)
Number of subjects: 23
Study 8003109 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-xylitol mixture (4 mg/kg BW/min)
Number of subjects: 23
Study 3582908 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine (10‐30 mg t.i.d.)
Number of subjects: 20
Study 3582908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 3582908 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 20
Study 3582908 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal esophageal contraction pressures
Number of subjects: 20
Study 29561290 — intervention group
Group type: EXPERIMENTAL
Intervention: CM for tobacco smoking
Number of subjects: 34
Study 29561290 — intervention group
Group type: EXPERIMENTAL
Intervention: CM for alcohol
Number of subjects: 34
Study 29561290 — intervention group
Group type: EXPERIMENTAL
Intervention: CM for smoking
Number of subjects: 34
Study 29561290 — intervention group
Group type: COMPARATOR
Intervention: NC for alcohol and tobacco smoking
Number of subjects: 34
Study 25423875 — intervention group
Group type: EXPERIMENTAL
Intervention: MICA-UKA (Group A)
Number of subjects: 87
Study 25423875 — intervention group
Group type: COMPARATOR
Intervention: MI-UKA (Group B)
Number of subjects: 87
Study 23943258 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-mode administration of SF-36
Number of subjects: 245
Study 23943258 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-mode administration of UCLA-PCI
Number of subjects: 245
Study 23943258 — intervention group
Group type: COMPARATOR
Intervention: Paper-mode administration of SF-36
Number of subjects: 245
Study 23943258 — intervention group
Group type: COMPARATOR
Intervention: Paper-mode administration of UCLA-PCI
Number of subjects: 245
Study 21773723 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee with high chlorogenic acid content
Number of subjects: 39
Study 21773723 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 39
Study 21773723 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee with regular chlorogenic acid
Number of subjects: 39
Study 21773723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 20403516 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (proficient in laparoscopic suturing)
Number of subjects: 20
Study 20403516 — intervention group
Group type: COMPARATOR
Intervention: Control group (not proficient in laparoscopic suturing)
Number of subjects: 20
Study 18544005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrabenazine treatment for 2 years
Number of subjects: 77
Study 18544005 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrabenazine treatment for a mean duration of 19 months
Number of subjects: 77
Study 16402873 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention for preschoolers at risk for conduct problems
Number of subjects: 92
Study 16402873 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 92
Study 12578937 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (Cr)
Number of subjects: 20
Study 12578937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10551653 — intervention group
Group type: EXPERIMENTAL
Intervention: FK506
Number of subjects: 80
Study 10551653 — intervention group
Group type: COMPARATOR
Intervention: CsA
Number of subjects: 80
Study 8686245 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 176
Study 8686245 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol
Number of subjects: 176
Study 8686245 — intervention group
Group type: EXPERIMENTAL
Intervention: Orimethen
Number of subjects: 176
Study 1725540 — intervention group
Group type: EXPERIMENTAL
Intervention: nisoldipine 10 mg b.i.d.
Number of subjects: 80
Study 1725540 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine 10 mg t.i.d.
Number of subjects: 80
Study 1725540 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine 20 mg t.i.d.
Number of subjects: 80
Study 1725540 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem 60 mg t.i.d.
Number of subjects: 80
Study 1725540 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem 120 mg t.i.d.
Number of subjects: 80
Study 1725540 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 40 mg q.i.d.
Number of subjects: 80
Study 6358886 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase therapy
Number of subjects: 250
Study 6358886 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 250
Study 30955358 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (involved in meals rehabilitation program)
Number of subjects: 123
Study 30955358 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual community aged care)
Number of subjects: 123
Study 29477151 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CaP supplementation
Number of subjects: 54
Study 29477151 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% CaP supplementation
Number of subjects: 54
Study 29477151 — intervention group
Group type: COMPARATOR
Intervention: Control without CaP supplementation
Number of subjects: 54
Study 26856808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus administration (40% of daily dose split into four equal boli applied every six hours, with 60% as background continuous infusion)
Number of subjects: 10
Study 26856808 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion (same pump parameters as during baseline evaluation)
Number of subjects: 10
Study 25390455 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thiamine (200 mg)
Number of subjects: 17
Study 22119706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Motor Activity Log - Quality of Movement (PMAL-QOM)
Number of subjects: 41
Study 22119706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Motor Activity Log - Amount of Use (PMAL-AOU)
Number of subjects: 41
Study 20175242 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified orotracheal intubation (Group M)
Number of subjects: 60
Study 20175242 — intervention group
Group type: COMPARATOR
Intervention: Conventional orotracheal intubation (Group C)
Number of subjects: 60
Study 20175242 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group M and Group C)
Number of subjects: 60
Study 17641566 — intervention group
Group type: EXPERIMENTAL
Intervention: Genuine acupuncture
Number of subjects: 135
Study 17641566 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (Streitberger needle)
Number of subjects: 135
Study 15613571 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (100 microg/kg plus 10 microg/kg/h)
Number of subjects: 126
Study 15613571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 15613571 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 126
Study 12586256 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous mechanical mitral commissurotomy (PMMC)
Number of subjects: 173
Study 10497668 — intervention group
Group type: EXPERIMENTAL
Intervention: Minolest (16.5 g/day)
Number of subjects: 83
Study 10497668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 7590572 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent tablet of sucralfate (2.0 g twice daily)
Number of subjects: 50
Study 7590572 — intervention group
Group type: COMPARATOR
Intervention: Granular formulation of sucralfate (2.0 g twice daily)
Number of subjects: 50
Study 7590572 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (effervescent and granular)
Number of subjects: 50
Study 1720917 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide or flecainide
Number of subjects: 2371
Study 1720917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2371
Study 7005682 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple protective isolation (437 days)
Number of subjects: 43
Study 7005682 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care (611 days)
Number of subjects: 43
Study 7005682 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple protective isolation
Number of subjects: 43
Study 7005682 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital care
Number of subjects: 43
Study 30846338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 0
Study 29193819 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag (maximum of 1,600 μg twice daily)
Number of subjects: 74
Study 29193819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 29193819 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 74
Study 25521772 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping and communication intervention
Number of subjects: 173
Study 25521772 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive counseling intervention
Number of subjects: 173
Study 24428912 — intervention group
Group type: EXPERIMENTAL
Intervention: PAHC questionnaire with feedback to genetic counselor
Number of subjects: 264
Study 24428912 — intervention group
Group type: COMPARATOR
Intervention: PAHC questionnaire without feedback to genetic counselor
Number of subjects: 264
Study 22328549 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic vasospasm (aVSP) severity graded as none, mild, moderate, or severe
Number of subjects: 409
Study 22328549 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic vasospasm (aVSP) severity
Number of subjects: 409
Study 19681414 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg/kg (Group R1)
Number of subjects: 32
Study 19681414 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 2 microg/kg (Group R2)
Number of subjects: 32
Study 19681414 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline (Group S)
Number of subjects: 32
Study 18078072 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (SelenoPRECISE, 200 microg daily for 16 weeks)
Number of subjects: 20
Study 15467529 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour intervention class on infant care and breastfeeding promotion
Number of subjects: 59
Study 15467529 — intervention group
Group type: COMPARATOR
Intervention: Class on infant care only (control group)
Number of subjects: 59
Study 16779740 — intervention group
Group type: EXPERIMENTAL
Intervention: aP vaccine
Number of subjects: 2
Study 16779740 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A vaccine (control)
Number of subjects: 2
Study 10367588 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol, 200 mg (beta1‐adrenoceptor partial agonist)
Number of subjects: 8
Study 10367588 — intervention group
Group type: EXPERIMENTAL
Intervention: prenalterol, 50 mg (beta1‐ and beta2‐adrenoceptor partial agonist)
Number of subjects: 8
Study 10367588 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol, 8 mg (beta2‐adrenoceptor partial agonist)
Number of subjects: 8
Study 10367588 — intervention group
Group type: COMPARATOR
Intervention: ICI 118,551, 25 mg (selective beta2‐adrenoceptor antagonist)
Number of subjects: 8
Study 10367588 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of partial agonists with ICI 118,551
Number of subjects: 8
Study 10367588 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8891938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (FG) application
Number of subjects: 11
Study 8891938 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline HCI (TTC) root conditioning only
Number of subjects: 11
Study 8891938 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 11
Study 1900381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pumping (IABP)
Number of subjects: 810
Study 1900381 — intervention group
Group type: COMPARATOR
Intervention: Control (no IABP)
Number of subjects: 810
Study 6510016 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release indomethacin (50 mg)
Number of subjects: 44
Study 6510016 — intervention group
Group type: COMPARATOR
Intervention: Diflunisal (250 mg)
Number of subjects: 44
Study 6510016 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 44
Study 30536189 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-youth (PY) intervention
Number of subjects: 532
Study 30536189 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-only (PO) intervention
Number of subjects: 532
Study 30536189 — intervention group
Group type: COMPARATOR
Intervention: Comparison (C) group
Number of subjects: 532
Study 28382785 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich plasma (PRP)
Number of subjects: 20